Pre-exposure (PrEP)
Pre-exposure Prophylaxis (PrEP)
Analysis Confirms Link Between PrEP Adherence and Reduced HIV Risk, Estimates Effective Dosing
- Details
- Category: HIV Prevention
- Published on Thursday, 20 September 2012 00:00
- Written by NIAID
Investigators with the iPrEx study, which demonstrated that pre-exposure prophylaxis (PrEP) using tenofovir/emtricitabine (Truvada) can dramatically lower the risk of HIV infection among gay and bisexual men, have now provided estimates of adherence levels need to achieve a high degree of protection. While more complete adherence is best, men may be able to reduce their HIV risk by 90% if they take Truvada 4 times weekly, or about every other day. 
ICAAC 2012: Long-acting Integrase Inhibitor S/GSK1265744 Active Against HIV Subtypes
- Details
- Category: HIV Treatment
- Published on Friday, 14 September 2012 00:00
- Written by Liz Highleyman
The experimental integrase inhibitor S/GSK1265744 exhibited potent and prolonged activity against a broad range of HIV subtypes, was active against clones with resistance to raltegravir (Isentress) and elvitegravir, and appears to have a high barrier to resistance, according to a presentation at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) this week in San Francisco.
AIDS 2012: Long-acting HIV Integrase Inhibitor S/GSK1265744 May Allow Monthly Dosing
- Details
- Category: HIV Treatment
- Published on Tuesday, 07 August 2012 00:00
- Written by Liz Highleyman
A nano-suspension formulation of the next-generation integrase inhibitor S/GSK1265744 demonstrated a half-life 21 to 50 days after a single injection, suggesting that once-monthly or even less frequent dosing may be possible, according to a poster presentation at the XIX International AIDS Conference (AIDS 2012) recently held in Washington, DC.
CDC Issues PrEP Guidance for Prevention of Heterosexual HIV Transmission
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Tuesday, 14 August 2012 00:00
- Written by Press Release
The U.S. Centers for Disease Control and Prevention (CDC) last week issued provisional guidance for the use of tenofovir/emtricitabine (Truvada) pre-exposure prophylaxis -- better known as PrEP -- to prevent heterosexual HIV transmission, adding to earlier guidelines issued for gay and bisexual men. The recommendations stress the importance of a negative HIV test prior to starting PrEP and a comprehensive package of prevention support.
New Guidance Addresses Expanded Antiretroviral Treatment, Perinatal ART, PrEP
- Details
- Category: HIV Treatment
- Published on Friday, 03 August 2012 00:00
- Written by Liz Highleyman
On the occasion of the XIX International AIDS Conference (AIDS 2012) last week in Washington, DC, the International Antiviral Society-USA (IAS-USA) released new guidelines recommending that all people diagnosed with HIV should be offered antiretroviral therapy (ART).
Web Design and Development by